Company Encyclopedia
View More
name
Exagen
XGN.US
Exagen Inc. designs, develops, and commercializes various testing products under the AVISE brand in the United States. The company enables healthcare providers to care for patients through the diagnosis, prognosis, and monitoring of complex rheumatic, and autoimmune and autoimmune-related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). Its lead testing product is AVISE CTD that enables differential diagnosis for patients presenting with symptoms indicative of various connective tissue diseases (CTDs) and other related diseases with overlapping symptoms.
1.946 T
XGN.USMarket value -Rank by Market Cap -/-

Financial Score

05/12/2025 Update
C
BiotechnologyIndustry
Industry Ranking131/394
Industry medianC
Industry averageD
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreD
    • ROE-122.81%E
    • Profit Margin-29.94%E
    • Gross Margin58.43%B
  • Growth ScoreB
    • Revenue YoY14.08%B
    • Net Profit YoY-12.48%D
    • Total Assets YoY44.07%A
    • Net Assets YoY40.95%A
  • Cash ScoreC
    • Cash Flow Margin-334.05%D
    • OCF YoY14.08%B
  • Operating ScoreA
    • Turnover1.2A
  • Debt ScoreD
    • Gearing Ratio71.13%D

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Exagen’s Strategic Growth and Innovation Drive Buy Rating Amid Market Expansion

    Exagen received a Buy rating from Kyle Mikson CFA at Canaccord Genuity, with a $15.00 price target, due to its strategic growth and innovation. The company showed strong Q3 2025 performance, expanding in existing accounts and acquiring new customers. Exagen operates in a promising market for autoimmune evaluations and is enhancing services and product innovation. BTIG also reiterated a Buy rating with the same price target.

    Tip Ranks·
    US
    XGN
    0.00%
    Tip Ranks·
    US
    XGN
    0.00%

    Exagen Inc. to Participate in Craig-Hallum Alpha Select Conference

    Exagen Inc. will participate in the 16th Annual Craig-Hallum Alpha Select Conference on November 18, 2025, at the Sheraton New York Times Square Hotel. Additionally, the company will attend the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum on November 20, 2025, at the Westin NY Grand Central. This announcement was published via GlobeNewswire on November 11, 2025.

    Reuters·
    US
    XGN
    0.00%
    Reuters·
    US
    XGN
    0.00%

    Exagen Inc. Reports Strong Q3 2025 Performance

    Exagen Inc. reported strong Q3 2025 performance with total revenue of $17.2 million, a 38% increase from Q3 2024. Key highlights include a 16% growth in AVISE CTD test volume and an average selling price of $441 per test. The company ended the quarter with $35.7 million in cash, despite a net loss of $7.1 million. Exagen aims for positive adjusted EBITDA by the end of 2025, with projected full-year revenue between $65 million and $70 million, focusing on growth and enhanced testing solutions.

    Tip Ranks·
    US
    XGN
    0.00%
    Tip Ranks·
    US
    XGN
    0.00%

    Exagen’s Earnings Call: Growth Amid Financial Hurdles

    Exagen's recent earnings call revealed a mix of strong operational growth and financial challenges. The company reported record fourth-quarter revenue of $17.2 million, a nearly 40% increase from the previous quarter, alongside significant testing volume growth and a rise in pharma services revenue. However, challenges include the loss of a high ASP account, slower ASP gains, and increased operating expenses, which may delay cash flow positivity until 2026. Despite these hurdles, Exagen remains focused on growth and innovation, with a positive outlook for 2025 revenue.

    Tip Ranks·
    US
    XGN
    0.00%
    Tip Ranks·
    US
    XGN
    0.00%

    Exagen’s Growth Potential Amid ASP Challenges: A Positive Long-Term Investment Outlook

    Exagen is viewed positively for long-term investment despite current average selling price (ASP) challenges. Revenue met expectations due to increased test volumes, which countered lower ASPs from a client shift to commercial insurance. Management aims for an ASP target of $600 and anticipates growth in test volumes. Analyst Daniel Brennan maintains an $18 price target, reflecting confidence in Exagen's value. He is a 5-star analyst with a 21.9% average return and a 57.81% success rate, covering the Healthcare sector.

    Tip Ranks·
    US
    XGN
    0.00%
    Tip Ranks·
    US
    XGN
    0.00%
    © 2025 Longbridge｜Disclaimer